

a<sup>3</sup>  
cont.  
granulomatous lung disease, emphysema, chronic fibrosing alveolitis, acute hyperoxic lung damage, multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, stroke, acute myocardial infarction, unstable angina, arterial restenosis, congestive heart failure, osteoporosis, osteoarthritis, glomerulonephritis, uveitis, Behçet's syndrome, sepsis, acute pancreatitis, diabetes, endometriosis, periodontal disease, heat stroke, glaucoma, multiple myeloma, myeloid leukemia, and combinations thereof.

In view of the amendment, Applicant requests favorable consideration of the application and speedy allowance of the claims.

Immunex Corporation  
Law Department  
51 University Street  
Seattle, WA 98101  
Telephone (206) 587-0430

Respectfully submitted,



Patricia Anne Perkins  
Registration No. 34,693

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on the date indicated below.

Date: December 13, 2007

By: \_\_\_\_\_



Camilla C. Edwards



RECEIVED  
DEC 20 2002  
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of: John E. Sims

Docket No.: 0315-C

Serial No.: 09/965,640

Group Art Unit: 164

Filing Date: October 27, 2001

Examiner: O. Chernyshev

For: IL-1 Delta DNA and Polypeptides

VERSION WITH MARKINGS TO SHOW AMENDMENTS

What is claimed is:

1. A method of treating an individual afflicted with an inflammatory and/or autoimmune disease comprising administering to the individual an IL-1 delta polypeptide selected from the group consisting of the ~~polypeptides of SEQ ID NO:2~~ and polypeptide of SEQ ID NO:4, and polypeptides encoded by DNAs that hybridize under moderately stringent conditions to the ~~DNAs of SEQ ID NO:1~~ or DNA of SEQ ID NO:3 and further wherein the polypeptides block an inflammatory response selected from the group consisting of rheumatoid arthritis and inflammatory bowel disease.

4. The method of claim 1, wherein the IL-1 delta polypeptides are selected from the group consisting of polypeptides comprising variant amino acid sequence that are at least 80% identical to the ~~polypeptides of SEQ ID NO:2~~, or polypeptide of SEQ ID NO:4.

5. The method of claim 2, wherein the IL-1 delta polypeptides are selected from the group consisting of polypeptides comprising variant amino acid sequence that are at least 80% identical to the ~~polypeptides of SEQ ID NO:2~~, or polypeptide of SEQ ID NO:4.

6. The method of claim 3, wherein the IL-1 delta polypeptides are selected from the group consisting of polypeptides comprising variant amino acid sequence that are at least 80% identical to the ~~polypeptides of SEQ ID NO:2~~, or polypeptide of SEQ ID NO:4.

7. The method of claim 1, wherein the IL-1 delta polypeptides are selected from the group consisting of polypeptides comprising the amino acid ~~sequences of SEQ ID NOs:2 or 4~~ sequence of SEQ ID NO:4 wherein the polypeptides comprise alterations to the amino acid ~~sequences~~ sequence selected from the group consisting of inactivated N-glycosylation site(s), inactivated protease processing site(s), conservative amino acid substitution(s), and combinations thereof.

8. The method of claim 2, wherein the IL-1 delta polypeptides are selected from the group consisting of polypeptides comprising the amino acid ~~sequences of SEQ ID NOs:2 or 4~~ sequence of SEQ ID NO:4 wherein the polypeptides comprise alterations to the amino acid ~~sequences~~ sequence selected from the group consisting of inactivated N-glycosylation site(s), inactivated protease processing site(s), conservative amino acid substitution(s), and combinations thereof.

9. The method of claim 3, wherein the IL-1 delta polypeptides are selected from the group consisting of polypeptides comprising the amino acid ~~sequences of SEQ ID NOs:2 or 4~~ sequence of SEQ ID NO:4 wherein the polypeptides comprise alterations to the amino acid ~~sequences~~ sequence selected from the group consisting of inactivated N-glycosylation site(s), inactivated protease processing site(s), conservative amino acid substitution(s), and combinations thereof.